These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 21045158)

  • 1. Alternative splicing of caspase 9 is modulated by the phosphoinositide 3-kinase/Akt pathway via phosphorylation of SRp30a.
    Shultz JC; Goehe RW; Wijesinghe DS; Murudkar C; Hawkins AJ; Shay JW; Minna JD; Chalfant CE
    Cancer Res; 2010 Nov; 70(22):9185-96. PubMed ID: 21045158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Molecular mechanism of erlotinib resistance in epidermal growth factor receptor mutant non-small cell lung cancer cell line H1650].
    Han R; Wang X; Zhong D; Zhao J; Chen Z; Sun L; Wang J; Zhang J
    Zhongguo Fei Ai Za Zhi; 2012 Dec; 15(12):689-93. PubMed ID: 23249714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy.
    Thomson S; Petti F; Sujka-Kwok I; Epstein D; Haley JD
    Clin Exp Metastasis; 2008; 25(8):843-54. PubMed ID: 18696232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
    Wong MH; Xue A; Julovi SM; Pavlakis N; Samra JS; Hugh TJ; Gill AJ; Peters L; Baxter RC; Smith RC
    Clin Cancer Res; 2014 Aug; 20(15):4047-58. PubMed ID: 24895459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SRSF1 regulates the alternative splicing of caspase 9 via a novel intronic splicing enhancer affecting the chemotherapeutic sensitivity of non-small cell lung cancer cells.
    Shultz JC; Goehe RW; Murudkar CS; Wijesinghe DS; Mayton EK; Massiello A; Hawkins AJ; Mukerjee P; Pinkerman RL; Park MA; Chalfant CE
    Mol Cancer Res; 2011 Jul; 9(7):889-900. PubMed ID: 21622622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation.
    Wang CY; Chao TT; Chang FY; Chen YL; Tsai YT; Lin HI; Huang YC; Shiau CW; Yu CJ; Chen KF
    Lung Cancer; 2014 Aug; 85(2):152-60. PubMed ID: 24954871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression.
    Sano Y; Hashimoto E; Nakatani N; Abe M; Satoh Y; Sakata K; Fujii T; Fujimoto-Ouchi K; Sugimoto M; Nagahashi S; Aoki M; Motegi H; Sasaki E; Yatabe Y
    Mol Cancer Ther; 2015 Feb; 14(2):533-41. PubMed ID: 25522765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells.
    Han W; Pan H; Chen Y; Sun J; Wang Y; Li J; Ge W; Feng L; Lin X; Wang X; Wang X; Jin H
    PLoS One; 2011; 6(6):e18691. PubMed ID: 21655094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Roles of MKK1/2-ERK1/2 and phosphoinositide 3-kinase-AKT signaling pathways in erlotinib-induced Rad51 suppression and cytotoxicity in human non-small cell lung cancer cells.
    Ko JC; Ciou SC; Jhan JY; Cheng CM; Su YJ; Chuang SM; Lin ST; Chang CC; Lin YW
    Mol Cancer Res; 2009 Aug; 7(8):1378-89. PubMed ID: 19671683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. hnRNP U enhances caspase-9 splicing and is modulated by AKT-dependent phosphorylation of hnRNP L.
    Vu NT; Park MA; Shultz JC; Goehe RW; Hoeferlin LA; Shultz MD; Smith SA; Lynch KW; Chalfant CE
    J Biol Chem; 2013 Mar; 288(12):8575-8584. PubMed ID: 23396972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gastrin-releasing peptide activates Akt through the epidermal growth factor receptor pathway and abrogates the effect of gefitinib.
    Liu X; Carlisle DL; Swick MC; Gaither-Davis A; Grandis JR; Siegfried JM
    Exp Cell Res; 2007 Apr; 313(7):1361-72. PubMed ID: 17349623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ubiquitin ligase Cbl-b is involved in icotinib (BPI-2009H)-induced apoptosis and G1 phase arrest of EGFR mutation-positive non-small-cell lung cancer.
    Mu X; Zhang Y; Qu X; Hou K; Kang J; Hu X; Liu Y
    Biomed Res Int; 2013; 2013():726375. PubMed ID: 23586056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells.
    Giovannetti E; Lemos C; Tekle C; Smid K; Nannizzi S; Rodriguez JA; Ricciardi S; Danesi R; Giaccone G; Peters GJ
    Mol Pharmacol; 2008 Apr; 73(4):1290-300. PubMed ID: 18187583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SRp30a (ASF/SF2) regulates the alternative splicing of caspase-9 pre-mRNA and is required for ceramide-responsiveness.
    Massiello A; Chalfant CE
    J Lipid Res; 2006 May; 47(5):892-7. PubMed ID: 16505493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer.
    Li YY; Lam SK; Mak JC; Zheng CY; Ho JC
    Lung Cancer; 2013 Sep; 81(3):354-361. PubMed ID: 23769318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The EGFR pathway regulates BCRP expression in NSCLC cells: role of erlotinib.
    Porcelli L; Giovannetti E; Assaraf YG; Jansen G; Scheffer GL; Kathman I; Azzariti A; Paradiso A; Peters GJ
    Curr Drug Targets; 2014; 15(14):1322-30. PubMed ID: 25479544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular and genetic studies imply Akt-mediated signaling promotes protein kinase CbetaII alternative splicing via phosphorylation of serine/arginine-rich splicing factor SRp40.
    Patel NA; Kaneko S; Apostolatos HS; Bae SS; Watson JE; Davidowitz K; Chappell DS; Birnbaum MJ; Cheng JQ; Cooper DR
    J Biol Chem; 2005 Apr; 280(14):14302-9. PubMed ID: 15684423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RAF1-MEK1-ERK/AKT axis may confer NSCLC cell lines resistance to erlotinib.
    Xu ZH; Hang JB; Hu JA; Gao BL
    Int J Clin Exp Pathol; 2013; 6(8):1493-504. PubMed ID: 23923067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2.
    Chen Y; Wu J; Yan H; Cheng Y; Wang Y; Yang Y; Deng M; Che X; Hou K; Qu X; Zou D; Liu Y; Zhang Y; Hu X
    Pharmacol Res; 2020 Sep; 159():105007. PubMed ID: 32561477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of the phosphatidylinositol 3-kinase/protein kinase B pathway in regulating alternative splicing of tissue factor mRNA in human endothelial cells.
    Eisenreich A; Malz R; Pepke W; Ayral Y; Poller W; Schultheiss HP; Rauch U
    Circ J; 2009 Sep; 73(9):1746-52. PubMed ID: 19597299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.